{"id":"W3016962124","doi":"10.1136/ejhpharm-2020-eahpconf.198","title":"4CPS-097 Secondline treatment of metastatic non-small cell lung cancer with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Rio Tinto","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Lung cancer; Nivolumab; Atezolizumab; Chemotherapy; Performance status; Retrospective cohort study; Cancer; Adverse effect; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002813006,0.0003575243,0.0009278412,0.00007140022,0.00007991667,0.00002051219,0.0001024241,0.0000587026,0.00105206],"category_scores_gemma":[0.00001063942,0.0002412514,0.0004478262,0.0003742426,0.00007262454,0.0001198307,0.00004282055,0.0002638317,0.00002664664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001044574,"about_ca_system_score_gemma":0.000244976,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002288447,"about_ca_topic_score_gemma":0.0002898037,"domain_scores_codex":[0.9975357,0.0001463442,0.001173563,0.0005636647,0.0002829455,0.000297794],"domain_scores_gemma":[0.9983329,0.0001838023,0.000565421,0.000294303,0.0001936082,0.0004299653],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02402975,0.01971618,0.7800916,0.01385671,0.01367997,0.0009241948,0.009053528,0.003525547,0.05762848,0.00001231372,0.001242792,0.07623888],"study_design_scores_gemma":[0.1229744,0.02671317,0.1022988,0.001278016,0.01887833,0.0001272028,0.003830937,0.05613391,0.5416508,0.00003150884,0.1245206,0.00156226],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897315,0.004012099,0.0001356273,0.003716846,0.0006488616,0.001201165,0.00009726449,0.00008515687,0.0003715005],"genre_scores_gemma":[0.992585,0.002086117,0.001830224,0.001939553,0.0009953633,0.0001200701,0.0001368308,0.00005387227,0.0002529679],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6777928,"threshold_uncertainty_score":0.9998611,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05666603131101178,"score_gpt":0.381958387943695,"score_spread":0.3252923566326832,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}